ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and
genomics company, today reported its financial and operational
results for the three months ended September 30, 2021.
Financial highlights for the quarter ended
September 30, 2021 include the following:
- Total revenue of
$9.5 million for the quarter ended September 30, 2021, as compared
to $3.8 million for the quarter ended September 30, 2020, an
increase of approximately 150%.
- 57,000
diagnostics tests were performed in the quarter ended September 30,
2021.
- Net loss of $4.0
million, or $(0.26) per share, for the quarter ended September 30,
2021, as compared to net loss of $0.6 million, or $(0.05) per
share, for the quarter ended September 30, 2020.
- Adjusted EBITDA
of $(1.3) million for the quarter ended September 30, 2021 as
compared to adjusted EBITDA of $(0.1) million for the quarter ended
September 30, 2020.
-
Cash, cash equivalents and marketable securities balance of $22.9M
and net working capital of $34.0M at September 30, 2021.
Corporate highlights for the quarter ended
September 30, 2021 and subsequently include the following:
- Acquired Nebula
Genomics, Inc., a privately owned personal genomics company, for
aggregate price of $14.6 million.
- Nebula
Co-Founder and Renowned Harvard Scientist, George Church, Ph.D., to
Spearhead ProPhase Labs New Scientific Advisory Board.
- Presented at five investor
conferences, including LD Micro, Benzinga Health Care Small Cap,
H.C. Wainwright Global, SNN Network Summer, and the Q3 Investor
Summit.
- Authorized the repurchase of up to
$6M in ProPhase common stock. As of November 10, 2021, the Company
has repurchased 140,769 shares at an aggregate amount of $791,000
or $5.62 per share
Ted Karkus, ProPhase’s Chief Executive Officer,
commented, “As we recently announced in an update to our
shareholders on October 13th, while the decline in the COVID-19
positivity rates continued through mid-Q3, it rebounded
significantly in late August and September. As a result, our
testing levels have recently increased significantly. Our testing
volumes in just the month of October alone surpassed the entire Q3
testing volumes. We anticipate that this surge will continue
through the remainder of Q4 based in part on our expanding customer
base, including municipal contract wins and the opening of schools
and other high-traffic venues, many of which will require either
vaccinations or regular COVID-19 testing to gain access.
“For the first nine months of the year, although
we recognized a net loss, our adjusted EBITDA was actually
positive. We also anticipate a very strong fourth quarter. We
believe that the winter months will bring about increased testing
based on the winter flu season gearing up, for which there may be
increased sensitivity to distinguish between the two viruses. We
are also building a sizable customer base of independent pharmacies
and concierge services that we anticipate will provide consistent
and growing testing revenues for our diagnostics business.”
“We are also proceeding as planned with our
integration of recently-acquired Nebula Genomics into our ProPhase
Precision Medicine division. We are confident that combining Nebula
Genomics’ comprehensive genomic testing with our CLIA-certified lab
capabilities will lead to faster turnaround times and lower price
points, driving additional demand. We also plan to offer low-pass
genomic testing at significantly lower price points. This will
allow us to leverage our distribution network of more than 40,000
food, drug, and mass retail stores to further expand
direct-to-consumer and big-box retail distribution of Nebula’s
genomic sequencing products and services. Each of these initiatives
could significantly grow sales as we look forward to 2022,” said
Mr. Karkus.
“The Company continues to be active in our
recently announced share repurchase program, which reflects the
Board of Directors’ confidence in both our current business
momentum and the future opportunities before us.”
“We are also continuing to evaluate and pursue
additional strategic and synergistic acquisitions to build our
precision medicine and genomics research capabilities with the help
of world-renowned genomics expert, George Church, co-founder of
Nebula Genomics and advisor to ProPhase,” concluded Mr. Karkus.
Financial
Results
Quarter Ended September
30, 2021
For the three months ended September 30, 2021,
net revenue was $9.5 million as compared to $3.8 million for the
three months ended September 30, 2020. We recognized higher net
revenue for the three months ended September 30, 2021 primarily as
a result of an increase of $7.1 million in revenue related to our
new diagnostic services business, which was offset by a decrease of
$2.5 million in customer orders from our consumer products business
as a result of the demand and inventory levels of third party
contract manufacturing customers.
Cost of revenues for the three months ended
September 30, 2021 was $5.5 million as compared to $2.8 million for
the three months ended September 30, 2020. For the three months
ended September 30, 2021 and 2020, we realized a gross margin of
42.0% and 27.1%, respectively. The increase in gross margin from
the prior period is principally due to increased margins generally
associated with our new diagnostic services business.
Diagnostic expenses for the three months ended
September 30, 2021 were $1.5 million compared to no diagnostics
expenses for the three months ended September 30, 2020. The $1.5
million in diagnostic expenses for the three months ended September
30, 2021 was comprised of network providers expenses associated
with our new diagnostic services business.
Sales, general and administration expenses for
the three months ended September 30, 2021 were $5.9 million as
compared to $1.6 million for the three months ended September 30,
2020. The increase of $4.3 million in general and administration
expenses was principally related to growth in personnel expenses
and professional fees associated with our new diagnostic services
business.
As a consequence of the effects of the above,
net loss from continuing operations for the three months ended
September 30, 2021 was $4.0 million, or $(0.26) per share, as
compared to the net loss from continuing operations for the three
months ended September 30, 2020 of $0.6 million, or $(0.05) per
share. Net income from discontinued operations was $161,000, or
$0.01 per share, for the three months ended September 30, 2020.
Our aggregate cash and cash equivalents,
restricted cash and marketable debt securities as of September 30,
2021 was $22.9 million as compared to $8.5 million at December 31,
2020. Our working capital was $34.0 million and $9.6 million as of
September 30, 2021 and December 31, 2020, respectively. The
increase of $14.4 million in our cash and cash equivalents,
restricted cash and marketable debt securities balance for the nine
months ended September 30, 2021 was principally due to our receipt
of aggregate net proceeds of $40.6 million from the issuance of
common stock and warrants in a registered direct offering and
public offering, and $10.7 million from the sale of marketable debt
securities, offset by (i) capital expenditures of $4.2 million,
(ii) cash dividend payments of $4.5 million, (iii) issuance of a
promissory note of $1.0 million, (iv) payment of $9.1 million
related to business acquisition, and (v) cash used in operations of
$9.0 million.
Conference Call and Webcast
DetailsManagement will host a conference call at 11:00 AM
ET today, November 12, 2021, to review financial results and
provide an update on corporate developments. Following management’s
formal remarks, there will be a question-and-answer session.
Participants can register for the conference
call by navigating
to: https://dpregister.com/sreg/10161532/ef2e0ef568
Please note that registered participants will
receive their dial in number upon registration and will dial
directly into the call without delay. Those without internet access
or unable to pre-register may dial in by calling: 1-866-777-2509
(domestic), or 1-412-317-5413 (international). All callers should
dial in approximately 10 minutes prior to the scheduled start time
and ask to be joined into ProPhase Labs call.
The conference call will be broadcast live and
available for replay
at https://services.choruscall.com/mediaframe/webcast.html?webcastid=ddkWfCfc and
via the investor relations section of the Company's website
at www.ProPhaseLabs.com.
A webcast replay of the call will be available
approximately two hours after the end of the call at the above
links. A telephonic replay of the call will be available and may be
accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088
(international) and using access code #10161532.
About ProPhase Labs
ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a
diversified biotech and genomics company that seeks to leverage its
CLIA lab services to provide whole genome sequencing and research
direct to consumers and build a genomics data base to be used for
further research. The Company continues to provide traditional CLIA
molecular laboratory services, including COVID-19 testing. ProPhase
Precision Medicine, Inc. focuses on genomics testing technologies,
a comprehensive method for analyzing entire genomes, including the
genes and chromosomes in DNA. The data obtained from genomic
testing can help to identify inherited disorders and tendencies,
help predict disease risk, help identify expected drug response,
and characterize genetic mutations, including those that drive
cancer progression.
ProPhase Diagnostics offers a broad array of
clinical diagnostic and testing services at its CLIA certified
laboratories. ProPhase Diagnostics serves patients who may have
SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods.
Critical to COVID testing, results are provided in under 24 hours.
ProPhase Diagnostics also offers PCR (polymerase chain reaction)
testing for Influenzas A and B and RSV; as well as antigen and
antibody/immunity tests to broaden its COVID-19 testing beyond
RT-PCR testing.
ProPhase Global Healthcare, Inc. was formed to
seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into
other countries and to pursue additional healthcare-related
initiatives.
ProPhase Labs has decades of experience
researching, developing, manufacturing, distributing, marketing,
and selling OTC consumer healthcare products and dietary
supplements, including dietary supplements under the TK
Supplements® brand. ProPhase actively pursues strategic
investments and acquisition opportunities for other companies,
technologies, and products. For more information,
visit www.ProPhaseLabs.com.
Forward Looking Statements
Except for the historical information contained
herein, this document contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding our strategy, plans,
objectives and initiatives, including statements regarding our
expectations with respect to Q4 COVID-19 testing revenues, our goal
to build a sizable customer base of independent pharmacies that
will provide consistent and growing testing revenues for our
diagnostics business, our plans to provide genomic testing with
faster turnaround times and lower price points resulting in
increased demand, our ability to leverage our distribution network
to expand direct-to-consumer and big-box retail distribution of
Nebula’s genomic sequencing products and services, and our ongoing
efforts to evaluate and pursue additional strategic and synergistic
acquisitions to build our precision medicine and genomics research
capabilities. Management believes that these forward-looking
statements are reasonable as and when made. However, such
forward-looking statements involve known and unknown risks,
uncertainties, and other factors that may cause actual results to
differ materially from those projected in the forward-looking
statements. These risks and uncertainties include but are not
limited to general economic conditions, the scale, scope and
duration of the COVID-19 pandemic, consumer demand for our COVID-19
testing and other lab processing services, challenges relating to
entering into new business lines, the competitive environment, our
failure to obtain and maintain necessary regulatory approvals, our
ability to continue to ramp up our labs’ testing capacity and
execute on our business plan, and the risk factors listed from time
to time in our Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q and any other SEC filings.
Media Relations Contact:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
ProPhase Labs, Inc. and
SubsidiariesCondensed Consolidated Balance
Sheets(in thousands, except share and per share
amounts)
|
|
September
30, |
|
|
December
31, |
|
|
|
2021 |
|
|
2020 |
|
|
|
(Unaudited) |
|
|
|
|
ASSETS |
|
|
|
|
|
|
Current
assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
8,533 |
|
|
$ |
6,816 |
|
Restricted cash |
|
|
250 |
|
|
|
- |
|
Marketable debt securities, available for sale |
|
|
14,114 |
|
|
|
1,639 |
|
Marketable equity securities, at fair value |
|
|
214 |
|
|
|
- |
|
Accounts receivable, net |
|
|
10,680 |
|
|
|
3,155 |
|
Inventory, net |
|
|
8,510 |
|
|
|
3,039 |
|
Prepaid expenses and other current assets |
|
|
1,602 |
|
|
|
1,238 |
|
Total
current assets |
|
|
43,903 |
|
|
|
15,887 |
|
|
|
|
|
|
|
|
|
|
Property,
plant and equipment, net |
|
|
6,454 |
|
|
|
3,578 |
|
Secured
promissory note receivable |
|
|
3,774 |
|
|
|
2,750 |
|
Prepaid
expenses, net of current portion |
|
|
460 |
|
|
|
2,084 |
|
Right-of-use
asset, net |
|
|
4,484 |
|
|
|
4,731 |
|
Intangible
assets, net |
|
|
11,562 |
|
|
|
1,234 |
|
Goodwill |
|
|
1,385 |
|
|
|
901 |
|
Other
assets |
|
|
608 |
|
|
|
240 |
|
TOTAL
ASSETS |
|
$ |
72,630 |
|
|
$ |
31,405 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current
liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,394 |
|
|
$ |
3,771 |
|
Accrued diagnostic services |
|
|
3,260 |
|
|
|
- |
|
Accrued advertising and other allowances |
|
|
344 |
|
|
|
463 |
|
Lease liabilities |
|
|
676 |
|
|
|
329 |
|
Deferred revenue |
|
|
1,517 |
|
|
|
- |
|
Other current liabilities |
|
|
1,741 |
|
|
|
1,731 |
|
Total
current liabilities |
|
|
9,932 |
|
|
|
6,294 |
|
|
|
|
|
|
|
|
|
|
Non-current
liabilities: |
|
|
|
|
|
|
|
|
Deferred revenue, net of current portion |
|
|
106 |
|
|
|
162 |
|
Note payable |
|
|
81 |
|
|
|
- |
|
Unsecured convertible promissory notes, net |
|
|
9,995 |
|
|
|
9,991 |
|
Lease liabilities, net of current portion |
|
|
4,252 |
|
|
|
4,402 |
|
Total
non-current liabilities |
|
|
14,434 |
|
|
|
14,555 |
|
Total
liabilities |
|
|
24,366 |
|
|
|
20,849 |
|
|
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
|
|
|
|
Preferred stock authorized 1,000,000, $.0005 par value, no shares
issued and outstanding |
|
|
- |
|
|
|
- |
|
Common stock authorized 50,000,000, $.0005 par value, 15,652,724
and 11,604,253 shares outstanding, respectively |
|
|
16 |
|
|
|
14 |
|
Additional paid-in capital |
|
|
103,807 |
|
|
|
61,674 |
|
Accumulated deficit |
|
|
(7,947 |
) |
|
|
(3,631 |
) |
Treasury stock, at cost, 16,652,022 and 16,652,022 shares,
respectively |
|
|
(47,490 |
) |
|
|
(47,490 |
) |
Accumulated other comprehensive loss |
|
|
(122 |
) |
|
|
(11 |
) |
Total stockholders' equity |
|
|
48,264 |
|
|
|
10,556 |
|
TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
$ |
72,630 |
|
|
$ |
31,405 |
|
ProPhase Labs, Inc. and
SubsidiariesCondensed Consolidated Statements of
Operations and Other Comprehensive
Loss(in thousands, except per share
amounts)(unaudited)
|
|
For the three months ended |
|
|
For the nine months ended |
|
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
Revenues, net |
|
$ |
9,472 |
|
|
$ |
3,840 |
|
|
$ |
33,885 |
|
|
$ |
9,351 |
|
Cost of revenues |
|
|
5,495 |
|
|
|
2,798 |
|
|
|
16,515 |
|
|
|
6,615 |
|
Gross profit |
|
|
3,977 |
|
|
|
1,042 |
|
|
|
17,370 |
|
|
|
2,736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostic expenses |
|
|
1,478 |
|
|
|
- |
|
|
|
6,117 |
|
|
|
- |
|
General and administration |
|
|
5,938 |
|
|
|
1,552 |
|
|
|
14,713 |
|
|
|
3,875 |
|
Research and development |
|
|
208 |
|
|
|
57 |
|
|
|
416 |
|
|
|
181 |
|
Total operating expenses |
|
|
7,624 |
|
|
|
1,609 |
|
|
|
21,246 |
|
|
|
4,056 |
|
Loss from operations |
|
|
(3,647 |
) |
|
|
(567 |
) |
|
|
(3,876 |
) |
|
|
(1,320 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income, net |
|
|
230 |
|
|
|
39 |
|
|
|
531 |
|
|
|
53 |
|
Interest expense |
|
|
(296 |
) |
|
|
(41 |
) |
|
|
(870 |
) |
|
|
(41 |
) |
Change in fair value of investment securities |
|
|
(265 |
) |
|
|
- |
|
|
|
(101 |
) |
|
|
- |
|
Loss from continuing operations |
|
|
(3,978 |
) |
|
|
(569 |
) |
|
|
(4,316 |
) |
|
|
(1,308 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued Operations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations |
|
|
- |
|
|
|
161 |
|
|
|
- |
|
|
|
161 |
|
Net loss |
|
$ |
(3,978 |
) |
|
$ |
(408 |
) |
|
$ |
(4,316 |
) |
|
$ |
(1,147 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized loss on marketable debt securities |
|
|
(33 |
) |
|
|
(8 |
) |
|
|
(111 |
) |
|
|
(2 |
) |
Total comprehensive loss |
|
$ |
(4,011 |
) |
|
$ |
(416 |
) |
|
$ |
(4,427 |
) |
|
$ |
(1,149 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations |
|
$ |
(0.26 |
) |
|
$ |
(0.05 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.11 |
) |
Income from discontinued operations |
|
|
- |
|
|
|
0.01 |
|
|
|
- |
|
|
|
0.01 |
|
Net loss per share |
|
$ |
(0.26 |
) |
|
$ |
(0.04 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.10 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
15,439 |
|
|
|
11,604 |
|
|
|
15,055 |
|
|
|
11,593 |
|
ProPhase Labs, Inc. and
SubsidiariesCondensed Consolidated Statements of
Cash Flows(in
thousands)(unaudited)
|
|
For the nine months ended |
|
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,316 |
) |
|
$ |
(1,147 |
) |
Adjustments to reconcile net loss to net cash provided by
(used in) operating activities: |
|
|
|
|
|
|
|
|
Realized (gain) loss on marketable debt securities |
|
|
40 |
|
|
|
(2 |
) |
Depreciation and amortization |
|
|
2,044 |
|
|
|
253 |
|
Amortization of debt discount |
|
|
4 |
|
|
|
- |
|
Amortization on right-of-use assets |
|
|
247 |
|
|
|
- |
|
Lower of cost or net realizable value inventory
adjustment |
|
|
- |
|
|
|
17 |
|
Stock-based compensation expense |
|
|
2,438 |
|
|
|
679 |
|
Change in fair value of investment securities |
|
|
(164 |
) |
|
|
- |
|
Non-cash interest income on secured promissory note
receivable |
|
|
(50 |
) |
|
|
- |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(7,327 |
) |
|
|
(1,015 |
) |
Escrow receivable |
|
|
- |
|
|
|
4,812 |
|
Inventory |
|
|
(5,036 |
) |
|
|
(696 |
) |
Prepaid and other assets |
|
|
1,639 |
|
|
|
(30 |
) |
Other assets |
|
|
(368 |
) |
|
|
- |
|
Accounts payable and accrued expenses |
|
|
(1,749 |
) |
|
|
470 |
|
Accrued diagnostic services |
|
|
3,260 |
|
|
|
- |
|
Deferred revenue |
|
|
1,461 |
|
|
|
|
|
Lease liabilities |
|
|
197 |
|
|
|
- |
|
Other liabilities |
|
|
(1,292 |
) |
|
|
835 |
|
Net cash (used in) provided by operating activities |
|
|
(8,972 |
) |
|
|
4,176 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Business acquisitions, net of cash acquired |
|
|
(9,066 |
) |
|
|
- |
|
Issuance of secured promissory note receivable |
|
|
(1,000 |
) |
|
|
(2,974 |
) |
Purchase of marketable securities |
|
|
(21,527 |
) |
|
|
(4,317 |
) |
Proceeds from sale of marketable debt securities |
|
|
10,701 |
|
|
|
3,839 |
|
Capital expenditures |
|
|
(4,258 |
) |
|
|
(222 |
) |
Net cash used in investing activities |
|
|
(25,150 |
) |
|
|
(3,674 |
) |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock from public offering,
net |
|
|
35,135 |
|
|
|
- |
|
Proceeds from issuance of common stock and warrants from
private offering |
|
|
5,500 |
|
|
|
- |
|
Proceeds from unsecured convertible promissory notes |
|
|
- |
|
|
|
10,000 |
|
Issuance costs on unsecured convertible promissory notes |
|
|
- |
|
|
|
(10 |
) |
Payment of issuance costs in connection with ATM |
|
|
- |
|
|
|
(66 |
) |
Payment of dividends |
|
|
(4,546 |
) |
|
|
- |
|
Net cash provided by financing activities |
|
|
36,089 |
|
|
|
9,924 |
|
|
|
|
|
|
|
|
|
|
Increase in cash, cash equivalents and restricted
cash |
|
|
1,967 |
|
|
|
10,426 |
|
Cash, cash equivalents and restricted cash, at the
beginning of the period |
|
|
6,816 |
|
|
|
434 |
|
Cash, cash equivalents and restricted cash, at the end
of the period |
|
$ |
8,783 |
|
|
$ |
10,860 |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures: |
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
$ |
- |
|
|
$ |
- |
|
Interest payment on the promissory notes |
|
$ |
750 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash investing and
financing activities: |
|
|
|
|
|
|
|
|
Issuance of common shares related to business
acqusition |
|
$ |
3,608 |
|
|
$ |
- |
|
Net unrealized loss, investments in marketable debt
securities |
|
$ |
(111 |
) |
|
$ |
(2 |
) |
Non-GAAP Financial Measure and
Reconciliation(in
thousands)(unaudited)
In an effort to provide investors with
additional information regarding our results of operations as
determined by accounting principles generally accepted in the
United States of America (“GAAP”), we disclose certain non-GAAP
financial measures. The primary non-GAAP financial measure we
disclose are EBITDA and Adjusted EBITDA.
We define EBITDA as net income (loss) before net
interest expense, income taxes, depreciation and amortization.
Adjusted EBITDA further adjusts EBITDA by excluding acquisition
costs, other non-cash items, and other unusual or non-recurring
charges (as described in the table below).
We use EBITDA and Adjusted EBITDA internally to
evaluate and manage the Company’s operations because we believe
they provide useful supplemental information regarding the
Company’s ongoing economic performance. We have chosen to provide
this information to investors to enable them to perform more
meaningful comparisons of operating results.
The following table sets forth the
reconciliations of EBITDA and Adjusted EBITDA excluding other costs
to the most comparable GAAP financial measures (in thousands):
|
|
For the three months ended |
|
|
For the nine months ended |
|
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
GAAP net loss (1) |
|
$ |
(3,978 |
) |
|
$ |
(408 |
) |
|
$ |
(4,316 |
) |
|
$ |
(1,147 |
) |
Interest, net |
|
|
65 |
|
|
|
2 |
|
|
|
339 |
|
|
|
(12 |
) |
Depreciation and amortization |
|
|
926 |
|
|
|
3 |
|
|
|
2,044 |
|
|
|
13 |
|
EBITDA |
|
|
(2,987 |
) |
|
|
(403 |
) |
|
|
(1,933 |
) |
|
|
(1,146 |
) |
Acquisition costs (2) |
|
|
674 |
|
|
|
- |
|
|
|
674 |
|
|
|
- |
|
Share-based compensation expense |
|
|
934 |
|
|
|
283 |
|
|
|
2,438 |
|
|
|
679 |
|
Non-cash rent expense (3) |
|
|
72 |
|
|
|
- |
|
|
|
443 |
|
|
|
- |
|
Adjusted EBITDA |
|
$ |
(1,307 |
) |
|
$ |
(120 |
) |
|
$ |
1,622 |
|
|
$ |
(467 |
) |
(1) We believe that net income (loss) is the
financial measure calculated and presented in accordance with GAAP
that is most directly comparable to EBITDA and Adjusted EBITDA.
EBITDA and Adjusted EBITDA measure the Company’s operating
performance without regard to certain expenses. EBITDA and Adjusted
EBITDA are not presentations made in accordance with GAAP and the
Company’s computation of EBITDA and Adjusted EBITDA may vary from
others in the industry. EBITDA and Adjusted EBITDA have important
limitations as analytical tools and should not be considered in
isolation or as substitutes for analysis of the Company’s results
as reported under GAAP.
(2) Transaction cost related to the Nebula
acquisition.
(3) The non-cash portion of rent, which reflects
the extent to which our GAAP rent expense recognized exceeds (or is
less than) our cash rent payments. For newer leases, our rent
expense recognized typically exceeds our cash rent payments, while
for more mature leases, rent expense recognized is typically less
than our cash rent payments.
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2023 to Apr 2024